Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD40 | P25942 | 1/20 | 0.38 |
| ▸ | CD40LG | P29965 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
| ▸ | CLK2 | P49760 | 1/20 | 0.30 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.30 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.30 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119640 | 0.84 | TDP1 (0.44) | ALDH1A1TSHR | |
| Water SCHEMBL30938808 | 0.82 | TDP1 (0.43) | CD40CD40LGALDH1A1 | |
| SCHEMBL3726621 | 0.82 | SLC2A1 (0.41) | CD40CD40LGALDH1A1 | |
| SCHEMBL446291 | 0.82 | MMP2 (0.42) | CD40CD40LGTSHR | |
| Ammonia Solution, Strong SCHEMBL6052079 | 0.82 | TDP1 (0.43) | CD40CD40LGALDH1A1 | |
| SCHEMBL8424370 | 0.82 | TDP1 (0.43) | CD40CD40LGALDH1A1 | |
| SCHEMBL9172322 | 0.81 | MMP2 (0.41) | CD40CD40LGTSHR | |
| SCHEMBL10347628 | 0.81 | TDP1 (0.42) | CD40CD40LGALDH1A1 | |
| SCHEMBL6052059 | 0.81 | PARP1 (0.39) | CD40CD40LG | |
| Silver SCHEMBL8424374 | 0.81 | CD40 (0.38) | CD40CD40LG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200063270-A1 | BIOCIDAL-FUNCTIONALIZED CORROSION INHIBITORS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2020-02-27 | — | — | US | claimed |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | SPRING MILL PHARMA, INC. | 2024-08-15 | — | — | US | disclosed |
| EP-4347607-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | Venatorx Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
| CN-107849044-B | Triaza-spirodecanones as DDR1 inhibitors | 豪夫迈·罗氏有限公司 | 2021-06-25 | — | — | CN | disclosed |
| WO-2021032323-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | GALAPAGOS NV (BE) | 2021-02-25 | — | — | WO | disclosed |
| EP-3782997-A1 | FUSED PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROTIC DISEASES | Galapagos N.V. (BE) | 2021-02-24 | — | — | EP | disclosed |
| EP-3317279-B1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| CN-107615144-B | Liquid crystal display device and alignment film | 夏普株式会社 | 2020-11-24 | — | — | CN | disclosed |
| US-20200063270-A1 | BIOCIDAL-FUNCTIONALIZED CORROSION INHIBITORS | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2020-02-27 | — | — | US | disclosed |
| US-10545382-B2 | Liquid crystal display device and alignment film | SHARP KABUSHIKI KAISHA (JP) | 2020-01-28 | — | — | US | disclosed |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-06-06 | — | — | US | disclosed |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | HOFFMAN LA-ROCHE INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180164616-A1 | LIQUID CRYSTAL DISPLAY DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180164616-A1 | LIQUID CRYSTAL DISPLAY DEVICE | SHARP KABUSHIKI KAISHA (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | HOFFMANN LA-ROCHE INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180149927-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND ALIGNMENT FILM | SHARP KABUSHIKI KAISHA (JP) | 2018-05-31 | — | — | US | disclosed |
| US-20180149927-A1 | LIQUID CRYSTAL DISPLAY DEVICE AND ALIGNMENT FILM | SHARP KABUSHIKI KAISHA (JP) | 2018-05-31 | — | — | US | disclosed |
| US-6166041-A | 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma | EURO-CELTIQUE, S.A. (LU) | 2000-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | CD40 2776/4885CD40LG 969/4885ALDH1A1 2654/4885 |
| US-20190169189-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | CD40 2798/4885CD40LG 1860/4885ALDH1A1 1320/4885 |
| US-20200063270-A1 | BIOCIDAL-FUNCTIONALIZED CORROSION INHIBITORS | SOD1, CAT, AOC1 | CD40 4356/4885CD40LG 3050/4885ALDH1A1 214/4885 |
| US-20180148450-A1 | TRIAZA-SPIRODECANONES AS DDR1 INHIBITORS | DDR1, DDR2, DDRGK1 | CD40 2798/4885CD40LG 1860/4885ALDH1A1 1320/4885 |
| US-10435407-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | CD40 2798/4885CD40LG 1860/4885ALDH1A1 1320/4885 |
| US-10239876-B2 | Triaza-spirodecanones as DDR1 inhibitors | DDR1, DDR2, DDRGK1 | CD40 2798/4885CD40LG 1860/4885ALDH1A1 1320/4885 |
| US-20240270762-A1 | PENICILLIN-BINDING PROTEIN INHIBITORS | PEPD, BPGM, EBPL | CD40 4485/4885CD40LG 4192/4885ALDH1A1 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.